The University of Oxford has paused administering doses of the COVID-19 vaccine it developed with AstraZeneca PLC in a small UK examine to check the shot in kids and youngsters, pending additional details about uncommon blood-clotting points in adults who’ve acquired it, the Wall Street Journal reported on Tuesday.
An Oxford spokesman informed the Journal that no issues of safety have arisen in the trial itself, however broader considerations about uncommon clotting issues in adults have triggered additional regulatory opinions in the UK and Europe to analyze any potential hyperlink with the vaccine.
